Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.83 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 3/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064664 | 0.91 | MCL1 (1.00) | MCL1AHRSLC9A1FDPSCCR2 | |
| SCHEMBL12168242 | 0.80 | AHR (0.62) | MCL1AHRKMT2AMEN1LMNA | |
| SCHEMBL30237959 | 0.80 | AHR (0.62) | MCL1AHRKMT2AMEN1LMNA | |
| SCHEMBL2347720 | 0.79 | MCL1 (0.54) | MCL1AHRKMT2AMEN1LMNA | |
| SCHEMBL8558281 | 0.77 | MCL1 (0.76) | MCL1AHRSLC9A1KMT2AMEN1 | |
| SCHEMBL25502516 | 0.77 | MCL1 (0.56) | MCL1AHRFDPSCCR2DAO | |
| SCHEMBL9559898 | 0.74 | MCL1 (0.56) | MCL1SLC9A1FDPSCCR2DAO | |
| SCHEMBL7952017 | 0.73 | MCL1 (0.48) | MCL1AHRSLC9A1LMNAALDH1A1 | |
| SCHEMBL7952021 | 0.72 | MCL1 (0.47) | MCL1AHRSLC9A1KMT2AMEN1 | |
| SCHEMBL12449714 | 0.72 | MCL1 (0.47) | MCL1AHRSLC9A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392574-B1 | Indolyl pyrrolidines for the treatment of cancer | ARQULE INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2173748-B1 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2173748-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | MCL1 92/4885AHR 3586/4885SLC9A1 3301/4885 |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | MKI67, POLI, DHPS | MCL1 277/4885AHR 2101/4885SLC9A1 4608/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | MCL1 78/4885AHR 3283/4885SLC9A1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.